CTRI/2020/09/027550已完成3 期
Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Prandial Technosphere® Insulin Inhalation Powder Versus Placebo Inhalation Powder in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs Over a 24-week Treatment Period.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Cipla Ltd
- 入组人数
- 216
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •A) At screening, for entering in the run-in period:
- •1.Subject/LAR is willing to sign the informed consent form
- •2.Male or female, aged 18 to 65 years (both inclusive)
- •3.Subject has been diagnosed with T2DM at least 12 months prior to screening visit
- •4.Receiving tolerated dose of OADs and on stable doses before enrollment.
- •5.Subject has HbA1c between 7.5% and 10.5% (both inclusive) and FPG <250 mg/dL.
- •6.No treatment with inhaled or injectable insulin, except during an acute illness, gestational diabetes
- •7.Subject agrees to have regular inhalations of insulin and use self-monitoring glucose device (glucometer) for recording blood glucose values as required by protocol.
- •8.Subject, in the opinion of the investigator, understands and is willing, able, and likely to comply with all study procedures and restrictions.
- •B) Subject has to satisfy the following glycemic criteria at the end of run-in period, prior to randomization to treatment period:
- •9.Subject has HbA1c between 7.5% and 10.5% (both inclusive) and FPG <250 mg/dL.
排除标准
- •1.Subject has BMI >35 kg/m2.
- •2.Subject has hypersensitivity to human insulin or any of its excipients.
- •3.Subject is diagnosed with asthma, chronic obstructive pulmonary disease, any other significant respiratory disease, or has FEV1/FVC <70% of predicted value.
- •4.Subject is a current smoker or has discontinued smoking within 6 months prior screening.
- •5.Subject has clinically significant abnormality on chest X-ray.
- •6.Use of glucagon-like peptide 1 receptor agonists, thiazolidinediones, or weight loss drugs in the past 3 months.
- •7.Subject has clinically significant major organ system disease.
- •8.Subject has had a myocardial infarction or stroke within 6 months prior to screening.
- •9.Subject is predisposed to severe hypoglycemia (=2 severe episodes within 6 months prior to screening) or has had any hospitalization or emergency department visit due to poor diabetes control within 6 months prior to screening.
- •10.Subject is currently using systemic glucocorticoids or other drugs that alter glucose metabolism
- •Note: Topical/ ophthalmic/ intraarticular/ nasal spray corticosteroids will be allowed.
- •11.Subject has a clinically significant abnormal ECG at screening.
- •12.Subject has clinically significant abnormal laboratory values for Liver function test, Renal function test and Thyroid stimulating hormone at screening.
- •13.Subject has history of recent blood transfusion or diagnosis of hemoglobinopathies
- •14.Subject has history of malignancy within 5 years of screening (other than basal cell carcinoma).
- •15.Subject is known to have any drug or alcohol dependence.
- •16.Subject is currently using or has used alternative or herbal medicines prior to screening.
- •17.Premenopausal women who:
- •a.are nursing or pregnant or
- •b.are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial.
- •c.Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems, oral, implantable, or injectable contraceptives, sexual abstinence, double barrier method and vasectomized partner.
- •18.Subject has participated in any clinical trial in last 3 months.
研究者
相似试验
招募中
3 期
A Study of Vaccination with 9-valent Extraintestinal Pathogenic Escherichia coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years And Older with a History of Urinary Tract Infection in the Past 2 YearsInvasive extraintestinal pathogenic Escherichia coli disease (IED) preventionpreventionJPRN-jRCT2031210272akano Masayoshi18,556
尚未招募
3 期
A Global Study to find out the Effects of a Test Vaccine on prevention of harmful diseases caused by E.Coli spreading outside of the gut in Adults who are 60 Years And Older with a History of Urinary Tract Infection in the Past 2 Years.CTRI/2023/11/059617Janssen Vaccines & Prevention B.V.
招募中
1 期
A study to evaluate ExPEC9V vaccine for the prevention of Invasive E. coli Disease in adults aged 60 years and older with a history of urinary tract infection in the past two years.Invasive Extraintestinal Pathogenic Escherichia coli DiseaseMedDRA version: 20.0Level: HLTClassification code: 10015295Term: Escherichia infections Class: 10021881MedDRA version: 21.1Level: PTClassification code: 10052238Term: Escherichia urinary tract infection Class: 100000004862CTIS2023-506589-30-00Janssen Vaccines & Prevention B.V.18,556
招募中
3 期
Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years And Older with a History of Urinary Tract Infection in the Past 2 Yearsurinary tract infectionNL-OMON56258Janssen Vaccines & Prevention B.V1,600
已完成
2 期
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder (REFRESH)CTRI/2012/08/002944Reviva Pharmaceuticals Inc228